Abstract
The glyoxalase enzymes represent a cellular defence system against the accumulation of cytotoxic α- oxoaldehydes leading to apoptosis. The potential of glyoxalase inhibitors to act as novel anti-cancer agents for drugresistant tumours that over-express glyoxalase is currently under investigation. In the present study, a series of 6- sulfamoylsaccharin and 1,2-benzoxathiine 2,2-dioxide (sulfocoumarin - coumarin bioisostere) derivates, as well as, transcinnamic acid (the mimic of coumarin hydrolysis product) have been tested for the inhibition of glyoxalase 1 and 2. For the first time, it has been demonstrated, that 6-sulfamoylsaccharin possesses glyoxalase 1 inhibitory activity (IC50=90±15 μM). Two compounds, 5b and 9c, slightly inhibited the activity of glyoxalase 2. In addition, it has been demonstrated that trans-cinnamic acid inhibits glyoxalase 1 activity (IC50=84±4 μM). These data indicate that the modification of 6- sulfamoylsaccharin structure and coumarin hydrolysis products can be used to develop potential glyoxalase 1 inhibitors.
Keywords: 1, 2-benzoxathiine 2, 2-dioxide, Glyoxalase 1, Glyoxalase 2, 6-sulfamoylsaccharin, Sulfocoumarin, Trans-cinnamic acid
Letters in Drug Design & Discovery
Title:Glyoxalase 1 and 2 Enzyme Inhibitory Activity of 6-Sulfamoylsaccharin and Sulfocoumarin Derivates
Volume: 10 Issue: 5
Author(s): Marina Makrecka, Raivis Zalubovskis, Edijs Vavers, Jekaterina Ivanova, Aiga Grandane and Maija Dambrova
Affiliation:
Keywords: 1, 2-benzoxathiine 2, 2-dioxide, Glyoxalase 1, Glyoxalase 2, 6-sulfamoylsaccharin, Sulfocoumarin, Trans-cinnamic acid
Abstract: The glyoxalase enzymes represent a cellular defence system against the accumulation of cytotoxic α- oxoaldehydes leading to apoptosis. The potential of glyoxalase inhibitors to act as novel anti-cancer agents for drugresistant tumours that over-express glyoxalase is currently under investigation. In the present study, a series of 6- sulfamoylsaccharin and 1,2-benzoxathiine 2,2-dioxide (sulfocoumarin - coumarin bioisostere) derivates, as well as, transcinnamic acid (the mimic of coumarin hydrolysis product) have been tested for the inhibition of glyoxalase 1 and 2. For the first time, it has been demonstrated, that 6-sulfamoylsaccharin possesses glyoxalase 1 inhibitory activity (IC50=90±15 μM). Two compounds, 5b and 9c, slightly inhibited the activity of glyoxalase 2. In addition, it has been demonstrated that trans-cinnamic acid inhibits glyoxalase 1 activity (IC50=84±4 μM). These data indicate that the modification of 6- sulfamoylsaccharin structure and coumarin hydrolysis products can be used to develop potential glyoxalase 1 inhibitors.
Export Options
About this article
Cite this article as:
Makrecka Marina, Zalubovskis Raivis, Vavers Edijs, Ivanova Jekaterina, Grandane Aiga and Dambrova Maija, Glyoxalase 1 and 2 Enzyme Inhibitory Activity of 6-Sulfamoylsaccharin and Sulfocoumarin Derivates, Letters in Drug Design & Discovery 2013; 10 (5) . https://dx.doi.org/10.2174/1570180811310050007
DOI https://dx.doi.org/10.2174/1570180811310050007 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Germinated Soybean Products as Nutraceutical Compounds in Breadmaking
Current Nutrition & Food Science Transport of Nucleoside Analogs Across the Plasma Membrane: A Clue to Understanding Drug-Induced Cytotoxicity
Current Drug Metabolism Retinoids as Critical Modulators of Immune Functions: New Therapeutic Perspectives for Old Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets The Impact of CRISPR/Cas9-Based Genomic Engineering on Biomedical Research and Medicine
Current Molecular Medicine Synthesis and Evaluation of New Thiazolyl Hydrazone Derivatives as Potential Anticancer Agents
Letters in Drug Design & Discovery Immune Response Manipulation: Recombinant Immunoreceptors Endow T-Cells with Predefined Specificity
Current Pharmaceutical Design GPR55 and its Interaction with Membrane Lipids: Comparison with Other Endocannabinoid-Binding Receptors
Current Medicinal Chemistry Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer’s Disease and Less Well-Known Diseases
Current Medicinal Chemistry Old Drugs-Current Perspectives
Current Pharmacogenomics Signal Transduction Therapy: Challenges to Clinical Trial Design
Current Signal Transduction Therapy Aminophosphonate Metal Complexes of Biomedical Potential
Current Medicinal Chemistry Dual Induction of Mitochondrial Apoptosis and Senescence in Chronic Myelogenous Leukemia by Myrtucommulone A
Anti-Cancer Agents in Medicinal Chemistry Immunity to Tumour Antigens
Current Pharmaceutical Design Advancement and Strategies for the Development of Peptide-drug Conjugates: Pharmacokinetic Modulation, Role and Clinical Evidence against Cancer Management
Current Cancer Drug Targets Antiproliferative Activity of Cobra Venom Cytotoxins
Current Topics in Medicinal Chemistry In Situ Gene Therapy for Prostate Cancer
Current Gene Therapy Whole Cell Biocatalysts for the Preparation of Nucleosides and their Derivatives
Current Pharmaceutical Design Reversing Breast Cancer Stem Cell into Breast Somatic Stem Cell
Current Pharmaceutical Biotechnology Tyrphostins as Potential Therapeutic Agents for Acute Kidney Injury
Current Medicinal Chemistry Flavonoids in Human Health: From Structure to Biological Activity
Current Nutrition & Food Science